Reports Q2 revenue $6B, consensus $5.93B. “We again delivered double-digit sales and adjusted earnings per share growth in the second quarter,” said Kevin Lobo, Chair and CEO. “Our strong sales and earnings power reflect demand for our products, our durable innovation pipeline and ongoing operational execution.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SYK:
- Notable companies reporting after market close
- Stryker’s Consistent Growth and Market Positioning Justify Buy Rating
- Roth MKM medical technology analyst holds analyst/industry conference call
- DoorDash, Southwest downgraded: Wall Street’s top analyst calls
- Zimmer Biomet upgraded to Buy from Neutral at Roth Capital